MK-3655 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Nov 11, 2020 → Apr 13, 2023
NCT ID
NCT04583423About MK-3655 + Placebo
MK-3655 + Placebo is a phase 2 stage product being developed by Merck for Nonalcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04583423. Target conditions include Nonalcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04583423 | Phase 2 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis